Form 4: Singular Genomics Systems Executive Exercises Stock Options
SEC Form 4 Filing
Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 250 shares of common stock through the settlement of vested Restricted Stock Units.
Summary
- On September 15, 2024, Eli N. Glezer, the Chief Scientific Officer of Singular Genomics Systems, Inc., acquired 250 shares of common stock.
- This acquisition resulted from the settlement of vested Restricted Stock Units (RSUs), where each RSU represents the right to receive one share of common stock.
- Following the transaction, Glezer directly owns 154,333 shares of Singular Genomics Systems, Inc.
- The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on June 26, 2024.
- The RSUs vest in 16 equal quarterly installments over four years, starting from March 15, 2023.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive stock ownership.
- The transaction has a negligible impact on employees, customers, suppliers, and creditors.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Start date for RSU vesting, occurring in 16 equal quarterly installments over four years. |
| June 26, 2024 | The Issuer effected a 1-for-30 reverse stock split of its common stock. |
| September 15, 2024 | Date of transaction: Eli N. Glezer acquired 250 shares of common stock through RSU settlement. |
| September 17, 2024 | Date of filing: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.